Most FSHD therapeutics under development require only a large animal model with consistent, inducible expression of DUX4-fl and its target genes in order to test target engagement, molecular efficacy, dosing, and delivery. Here, DUX4 is linked to facioscapulohumeral muscular dystrophy.